Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.

Barban V, Mantel N, De Montfort A, Pagnon A, Pradezynski F, Lang J, Boudet F.

J Virol. 2018 May 29;92(12). pii: e00440-18. doi: 10.1128/JVI.00440-18. Print 2018 Jun 15.

2.

Vaccination Against Dengue: Challenges and Current Developments.

Guy B, Lang J, Saville M, Jackson N.

Annu Rev Med. 2016;67:387-404. doi: 10.1146/annurev-med-091014-090848. Epub 2015 Oct 23. Review.

PMID:
26515983
3.

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.

Guy B, Briand O, Lang J, Saville M, Jackson N.

Vaccine. 2015 Dec 10;33(50):7100-11. doi: 10.1016/j.vaccine.2015.09.108. Epub 2015 Oct 20. Review.

4.

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.

Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J.

Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131.

5.

Efficacy of a tetravalent dengue vaccine in children in Latin America.

Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortés Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F; CYD15 Study Group.

N Engl J Med. 2015 Jan 8;372(2):113-23. doi: 10.1056/NEJMoa1411037. Epub 2014 Nov 3.

6.

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A; CYD14 Study Group.

Lancet. 2014 Oct 11;384(9951):1358-65. doi: 10.1016/S0140-6736(14)61060-6. Epub 2014 Jul 10.

PMID:
25018116
7.

Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.

Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP.

Viruses. 2013 Dec 9;5(12):3048-70. doi: 10.3390/v5123048. Review.

8.

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.

Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, Li Ng J, Yun Toh X, Archuleta S, Wilder-Smith A, Shek LP, Wartel-Tram A, Bouckenooghe A, Lang J, Crevat D, Caillet C, Guy B.

Hum Vaccin Immunother. 2013 Nov;9(11):2317-25. Epub 2013 Jul 9.

9.

Efficacy of tetravalent dengue vaccine in Thai schoolchildren - Authors' reply.

Sabchareon A, Wallace D, Lang J, Bouckenooghe A, Moureau A.

Lancet. 2013 Mar 30;381(9872):1094-5. doi: 10.1016/S0140-6736(13)60755-2. No abstract available.

PMID:
23540847
10.

Q&A session 06 October 2011: I International Symposium on Dengue, FMUSP, São Paulo.

Lang J, Bricks LF, Coelho G.

Rev Inst Med Trop Sao Paulo. 2012 Oct;54 Suppl 18:S28-30. No abstract available.

11.

Development of Sanofi Pasteur tetravalent dengue vaccine.

Lang J.

Rev Inst Med Trop Sao Paulo. 2012 Oct;54 Suppl 18:S15-7. No abstract available.

12.

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J.

Lancet. 2012 Nov 3;380(9853):1559-67. doi: 10.1016/S0140-6736(12)61428-7. Epub 2012 Sep 11.

PMID:
22975340
13.

Evaluation of chimeric yellow fever 17D/dengue viral replication in ticks.

Kazimírová M, Mantel N, Raynaud S, Slovák M, Ustaniková K, Lang J, Guy B, Barban V, Labuda M.

Vector Borne Zoonotic Dis. 2012 Nov;12(11):979-85. doi: 10.1089/vbz.2011.0947. Epub 2012 Aug 27.

PMID:
22925017
14.

Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.

Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, Claude JB, Lang J.

Virology. 2012 Aug 1;429(2):91-8. doi: 10.1016/j.virol.2012.03.007. Epub 2012 Apr 25.

15.

Assessing the potential of a candidate dengue vaccine with mathematical modeling.

WHO-VMI Dengue Vaccine Modeling Group, Beatty M, Boni MF, Brown S, Buathong R, Burke D, Coudeville L, Cummings DA, Edelman R, Farrar J, Focks DA, Gomes MG, Guignard A, Halstead S, Hombach J, Knerer G, Koelle K, Lam FC, Lang J, Longini I, Medlock J, Namgyal P, Powell M, Recker M, Rohani P, Standaert B, Struchiner C, Teyssou R, Wearing H.

PLoS Negl Trop Dis. 2012;6(3):e1450. doi: 10.1371/journal.pntd.0001450. Epub 2012 Mar 27. No abstract available.

16.

Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.

Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J.

Am J Trop Med Hyg. 2011 Oct;85(4):724-31. doi: 10.4269/ajtmh.2011.10-0436.

17.

Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting.

Lam SK, Burke D, Capeding MR, Chong CK, Coudeville L, Farrar J, Gubler D, Hadinegoro SR, Hanna J, Lang J, Lee HL, Leo YS, Luong CQ, Mahoney R, McBride J, Mendez-Galvan J, Ng LC, Nimmannitya S, Ooi EE, Shepard D, Smit J, Teyssou R, Thomas L, Torresi J, Vasconcelos P, Wirawan DN, Yoksan S.

Vaccine. 2011 Nov 28;29(51):9417-22. doi: 10.1016/j.vaccine.2011.08.047. Epub 2011 Aug 22.

18.

Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus.

McGee CE, Tsetsarkin KA, Guy B, Lang J, Plante K, Vanlandingham DL, Higgs S.

PLoS One. 2011;6(8):e23247. doi: 10.1371/journal.pone.0023247. Epub 2011 Aug 3.

19.

Decay and persistence of maternal dengue antibodies among infants in Bangkok.

van Panhuis WG, Luxemburger C, Pengsaa K, Limkittikul K, Sabchareon A, Lang J, Durbin AP, Cummings DA.

Am J Trop Med Hyg. 2011 Aug;85(2):355-62. doi: 10.4269/ajtmh.2011.11-0125.

20.

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J.

Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Review.

PMID:
21745521

Supplemental Content

Loading ...
Support Center